LCP
EBS icon

Lombardia Capital Partners’s Emergent Biosolutions EBS Stock Holding History

Lombardia Capital Partners’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$1.04M Sell
35,736
-236,729
-87% -$7.21M 0.94% 45
2016
Q4 		$8.95M Buy
272,465
+15,087
+6% +$452K 0.92% 53
2016
Q3 		$8.12M Buy
257,378
+237,420
+1,190% +$6.9M 0.55% 76
2016
Q2 		$561K Sell
19,958
-2,645
-12% -$104K 0.04% 162
2016
Q1 		$822K Buy
+22,603
New +$798K 0.04% 160

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lombardia Capital Partners's EBS Position: Q1 2017 in Review

Lombardia Capital Partners reduced its Emergent Biosolutions (EBS) stake by 87% in Q1 2017, selling an estimated $7.21M and leaving 35,736 shares worth $1.04M. The position accounts for 0.94% of the portfolio, ranked #45.

Lombardia Capital Partners first reported a position in EBS in Q1 2016 and has held it in 5 quarters since. The position peaked at $8.95M in Q4 2016. 176 funds tracked by Wall St. Rank hold EBS as of Q1 2017.

  • Lombardia Capital Partners held 35,736 shares of Emergent Biosolutions worth $1.04M as of Q1 2017.
  • Lombardia Capital Partners sold 236,729 Emergent Biosolutions shares in Q1 2017, an estimated $7.21M.
  • Emergent Biosolutions made up 0.94% of Lombardia Capital Partners's portfolio in Q1 2017, its #45 holding.
  • Lombardia Capital Partners first reported a position in Emergent Biosolutions in Q1 2016 and has held it in 5 quarters since.
  • Lombardia Capital Partners's Emergent Biosolutions position peaked at $8.95M in Q4 2016.
  • 176 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2017.

Based on Lombardia Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.